Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH)

Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare, inherited condition that makes the kidneys lose too much phosphate in the urine. Because phosphate is lost, the level of phosphate in the blood becomes low (hypophosphatemia). Bones need phosphate to grow strong. When phosphate stays low for a long time in children, bones become soft and bend easily (rickets). In adults, bones can ache and break more easily (osteomalacia).

Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare, inherited kidney condition. The kidneys lose too much phosphate into urine (called “phosphate wasting”). Low blood phosphate weakens growing bone and can cause bowed legs, delayed growth, bone pain, and fractures. At the same time, the body makes extra active vitamin D (1,25-dihydroxyvitamin D), which increases calcium absorption and leads to high calcium in the urine (hypercalciuria) and kidney stones or nephrocalcinosis. HHRH is usually caused by mutations in the SLC34A3 gene, which encodes the NaPi-IIc phosphate transporter in the kidney; it is typically inherited in an autosomal recessive pattern. Unlike the more common X-linked hypophosphatemia, HHRH does not have high FGF23; instead, 1,25-dihydroxyvitamin D is “appropriately” high for the low phosphate state. edm.bioscientifica.com+3PubMed+3PubMed+3

HHRH happens because of changes (mutations) in a kidney phosphate transporter called NaPi-IIc, which is made by the SLC34A3 gene. When this transporter does not work well, the kidney cannot keep (reabsorb) phosphate. The body senses the low phosphate and responds by making more of the active form of vitamin D (1,25-dihydroxyvitamin D). That active vitamin D increases calcium absorption from the gut, so more calcium enters the body and then spills into urine, leading to hypercalciuria (high calcium in urine), kidney stones, or calcium deposits in the kidneys (nephrocalcinosis). In HHRH, a hormone called FGF23 is usually low or not high; this helps doctors tell HHRH apart from other forms of hypophosphatemic rickets that are driven by high FGF23. kireports.org+3PMC+3BioMed Central+3

HHRH is usually autosomal recessive. That means a person is affected when they inherit a nonworking SLC34A3 copy from each parent. People with only one changed copy (carriers) can sometimes have mild phosphate lowering and kidney calcium loss, and may form stones. ScienceDirect+2journals.physiology.org+2

---

Other names

• NaPi-IIc deficiency (refers to the kidney phosphate transporter that is affected). ScienceDirect

• SLC34A3-related hypophosphatemic rickets (names the gene). Cell

• FGF23-independent hypophosphatemic rickets (tells us FGF23 is not driving the problem). OUP Academic+1

• OMIM #241530 (catalog number often used in genetics). PubMed

---

Types

1) By genetics and severity.

• Biallelic (two faulty copies): the classic, childhood-onset form, with low blood phosphate, rickets/osteomalacia, high urine calcium, and often kidney stones or nephrocalcinosis. ScienceDirect

• Monoallelic (one faulty copy, “carrier”): may be symptom-free or show kidney stones or hypercalciuria and sometimes mild low phosphate. The severity is often milder and variable. journals.physiology.org+1

2) By age at presentation.

• Pediatric-onset HHRH: short height, bowed legs, bone pain, delayed walking, and wrist/ankle swelling. BioMed Central

• Adolescent/adult-onset HHRH: bone pain, stress fractures, kidney stones, or nephrocalcinosis may be the first clues. PMC

3) By organ impact.

• Skeletal-dominant: rickets/osteomalacia, limb deformities, fractures.

• Renal-dominant: hypercalciuria, nephrolithiasis (stones), nephrocalcinosis. Many patients show features from both. PMC+1

---

Causes

Important note: The root cause of HHRH is pathogenic variants in SLC34A3 that reduce the kidney’s ability to reabsorb phosphate. The items below start with that cause and then list well-documented contributors that worsen, reveal, or modify the condition. I’m keeping the language simple and consistent with the medical literature. ScienceDirect+1

1. Biallelic SLC34A3 (NaPi-IIc) loss-of-function: the defining cause of HHRH. ScienceDirect

2. Compound-heterozygous SLC34A3 variants: two different harmful variants, one from each parent. PubMed

3. Homozygous SLC34A3 variants: the same variant on both copies. ScienceDirect

4. Gene-dosage effects: one variant (carriers) can still cause hypercalciuria or stones in some people. journals.physiology.org+1

5. Specific missense variants that weaken transport (many have been reported across families worldwide). ScienceDirect+1

6. Splice-site variants causing improperly processed transporter RNA. PMC

7. Intronic variants affecting expression documented in newer case studies. ScienceDirect

8. Low dietary phosphate can worsen the low phosphate state in those with HHRH. (Not a primary cause, but it aggravates the problem.) PMC

9. Vitamin D deficiency can mask the usual lab pattern and delay recognition of HHRH. PMC+1

10. High vitamin D intake can increase calcium absorption and make urine calcium even higher. (Aggravates hypercalciuria.) PMC

11. High sodium intake often increases urinary calcium and may worsen stones in hypercalciuric states. (General kidney stone physiology applied to HHRH.) PMC

12. Low fluid intake/dehydration can favor stone formation in people with hypercalciuria. PMC

13. Periods of rapid growth (childhood, adolescence) increase phosphate needs and make symptoms more obvious. BioMed Central

14. Pregnancy can increase mineral demands; case reports note variable effects in phosphate-wasting conditions. (Supportive, context-level evidence.) ASBMR

15. High calcium supplements may worsen hypercalciuria and stones in HHRH. (Context from disease physiology.) PMC

16. Thiazide diuretics withdrawn (if previously used) can unmask higher urinary calcium; conversely, thiazides sometimes reduce calciuria. (General stone physiology, applied cautiously.) PMC

17. Concurrent renal tubular stress (e.g., other tubulopathies) could amplify phosphate loss. (Differential discussions.) PMC

18. Mis-treatment with calcitriol given for “rickets” without recognizing HHRH can raise 1,25-(OH)₂D further and worsen hypercalciuria. PMC

19. Family clustering and founder variants: some communities carry shared SLC34A3 variants. ScienceDirect

20. Modifier genes affecting mineral handling (research/observational): can shape severity among relatives with similar SLC34A3 variants. ASBMR

---

Common symptoms and signs

1. Bone pain (legs, hips, back). Soft bone makes everyday movement hurt. BioMed Central

2. Bowing of the legs (genu varum/valgum) in children due to rickets. BioMed Central

3. Delayed walking or motor milestones in toddlers. BioMed Central

4. Shorter height than peers if rickets is untreated. BioMed Central

5. Wrist and ankle swelling from widened growth plates. BioMed Central

6. Muscle weakness or tired legs. Soft bone and low phosphate reduce strength. BioMed Central

7. Fractures or stress fractures, especially in adolescents or adults. BioMed Central

8. Gait problems (waddling or limp). BioMed Central

9. Dental enamel problems or tooth pain can occur in rickets/osteomalacia states. MedlinePlus

10. Kidney stones (pain, blood in urine) from high urine calcium. PMC

11. Nephrocalcinosis (calcium deposits in kidney tissue), sometimes without symptoms at first. PMC

12. Frequent urination or urgent urination with stones. PMC

13. Back or flank pain from stones or nephrocalcinosis. PMC

14. Poor bone healing after minor injuries in adults. BioMed Central

15. Family history of kidney stones or short stature/leg bowing (may suggest carriers or affected relatives). journals.physiology.org

---

Diagnostic tests

A) Physical examination (how the doctor looks, listens, and feels)

1. Growth and height charting.
   Doctors measure height and plot it on a chart for age. Children with long-standing rickets may fall below their expected height line. Tracking the curve over time shows if treatment helps. BioMed Central

2. Limb alignment check (leg bowing).
   By observing how the knees and ankles line up when standing, doctors can see varus/valgus deformities caused by soft growth plates. They also look at how the alignment changes with age and treatment. BioMed Central

3. Wrist/ankle growth-plate exam.
   Rickets widens the growth plates, which can look and feel fuller. The doctor gently examines these joints for swelling and tenderness. BioMed Central

4. Gait assessment (how a person walks).
   A waddling or limping gait suggests hip or leg pain or deformity. Improvement after phosphate therapy supports the diagnosis. BioMed Central

5. Muscle strength testing.
   Simple resistance tests in arms and legs check for weakness related to low phosphate and soft bone pain. BioMed Central

B) Bedside/manual assessments (quick clinic tests without machines)

6. Range-of-motion testing of hips/knees/ankles.
   Limited motion can come from pain, deformity, or soft bone near joints. Gentle movement testing helps locate the problem. BioMed Central

7. Tenderness mapping over long bones.
   Pressing gently along shins, thighs, or arms may show diffuse bony tenderness—common in osteomalacia and active rickets. BioMed Central

8. Posture and spine screening.
   Rickets/osteomalacia can alter posture from pain or deformity. A quick look helps decide if spine X-rays are needed. BioMed Central

9. Stone symptom screen.
   Simple bedside checks—asking about colicky pain, blood in urine, urinary frequency—can point to kidney stones and guide imaging. PMC

10. Hydration status and blood pressure.
    Because stones and nephrocalcinosis involve the kidneys, doctors measure blood pressure and hydration; this also frames safe care. PMC

C) Laboratory and pathological tests (key for HHRH)

11. Serum phosphate (low).
    This is the central lab finding. In HHRH, phosphate is low because kidneys waste phosphate. BioMed Central

12. Serum calcium (often normal) and alkaline phosphatase (often high in children).
    Calcium is usually normal; alkaline phosphatase rises when bones remodel actively, especially in rickets. BioMed Central

13. PTH (parathyroid hormone) (low-normal).
    In HHRH, PTH is not driving the problem and is often normal or low-normal—different from some other rickets types. PMC

14. 1,25-dihydroxyvitamin D (high).
    This active vitamin D form tends to be elevated in HHRH, which helps separate it from FGF23-driven rickets (where this level is low or inappropriately normal). PMC

15. 25-hydroxyvitamin D (to check for deficiency).
    Low 25-OH vitamin D can mask HHRH lab patterns; it must be checked and corrected to read labs correctly. PMC

16. Urine calcium/creatinine ratio (high).
    High urine calcium is very common in HHRH and supports the diagnosis and the risk for stones. PMC

17. Tubular maximum for phosphate per GFR (TmP/GFR).
    This calculation shows how well the kidney holds onto phosphate. In HHRH it is low, proving renal phosphate wasting. ASBMR

18. Urine phosphate and urinalysis.
    These help document phosphate wasting and screen for blood or crystals when stones are suspected. PMC

19. FGF23 level (often low or not elevated).
    A low/normal FGF23 suggests HHRH rather than FGF23-excess disorders like XLH; this is very helpful in the differential diagnosis. kireports.org

20. Genetic testing of SLC34A3.
    Finding two harmful SLC34A3 variants confirms HHRH. Testing can use gene panels, exome, or targeted SLC34A3 sequencing. ScienceDirect

D) Electrodiagnostic tests (why they are not routine here)

1. There are no specific electrodiagnostic tests (like EMG or nerve conduction) used to diagnose HHRH. These studies are for nerve or muscle electrical function. HHRH is diagnosed by blood/urine tests, imaging, and genetics, so electrodiagnostics are not routinely indicated unless another problem is suspected. This distinction helps avoid unnecessary testing. PMC

E) Imaging tests (to look at bones and kidneys)

1. X-rays of wrists, knees, and long bones.
   Doctors look for classic rickets changes: widened growth plates, metaphyseal fraying and cupping, and bowing. In adults, they may see Looser’s zones (pseudofractures). BioMed Central

2. Renal ultrasound.
   An important, radiation-free test to check for kidney stones and nephrocalcinosis in people with hypercalciuria. PMC

3. Skeletal survey (selected views).
   Sometimes used to map bone involvement in children with widespread symptoms or to plan orthopedic care. BioMed Central

4. DXA scan (bone density).
   DXA can show low bone mineral density due to chronic phosphate loss and helps track response to treatment over time. ASBMR

5. CT KUB (non-contrast) when stones are suspected and ultrasound is unclear.
   CT is very sensitive for stones but involves radiation, so it’s reserved for selected cases. PMC

Non-pharmacological treatments (therapies and other)

1. Phosphate-aware nutrition coaching – Work with a dietitian to include phosphate-containing foods (e.g., lean meats, dairy if tolerated) that fit your total plan alongside prescribed oral phosphate. Purpose: support bone mineralization and reduce symptoms. Mechanism: dietary phosphate complements prescribed phosphate to improve serum levels; clinicians balance this with kidney stone risk. PMC

2. High-fluid intake – Aim for urine output ≥2 liters/day (age-adjusted for children as advised by clinician). Purpose: dilute urinary calcium and phosphate to lower stone risk. Mechanism: increased flow decreases crystal supersaturation; this principle underpins stone prevention advice and is reflected in labels for citrate therapy that pair medication with high fluid and salt restriction. FDA Access Data

3. Low-sodium diet – Reduce added salt and very salty foods. Purpose: lower urinary calcium. Mechanism: sodium and calcium excretion are coupled in the kidney; less sodium in the diet helps kidneys reabsorb more calcium, lowering urinary calcium and stone risk (this is bundled with citrate label instructions). FDA Access Data

4. Orthopedic bracing (when indicated by orthopedics) – Temporary limb bracing in growing children. Purpose: support alignment and function while bones remineralize. Mechanism: external support reduces deforming forces on softened bone, complementing phosphate therapy. PMC

5. Physiotherapy for strength and gait – Progressive, low-impact strengthening and gait training. Purpose: reduce pain, improve mobility and balance, and support safe activity. Mechanism: loading within safe limits stimulates bone and muscle while minimizing fracture risk in hypophosphatemic bone. PMC

6. Fall-prevention home modifications – Remove tripping hazards, improve lighting, and use handrails. Purpose: prevent fractures in weakened bone. Mechanism: lowers the probability of high-impact events while bone heals with therapy. PMC

7. Kidney stone education – Learn early signs (flank pain, blood in urine) and when to get urgent care. Purpose: catch stones early and protect kidney function. Mechanism: timely imaging and urology referral reduce obstruction time and kidney damage. PMC

8. Regular imaging surveillance – Periodic renal ultrasound for stones/nephrocalcinosis, and skeletal radiographs in growing children when clinically indicated. Purpose: track complications. Mechanism: imaging detects changes driven by hypercalciuria and rickets early. PMC

9. Avoid unnecessary active vitamin D analogs – Unless a specialist specifically advises, avoid calcitriol/alfacalcidol in HHRH. Purpose: prevent worsening hypercalciuria and kidney calcifications. Mechanism: active vitamin D increases intestinal calcium absorption and urinary calcium. PMC

10. Safe sun practices & baseline vitamin D sufficiency – Maintain general vitamin D sufficiency with standard, clinician-guided measures if deficient, without overtreatment. Purpose: support overall bone health without raising urinary calcium excessively. Mechanism: physiologic vitamin D supports calcium-phosphate balance; excessive active analogs are avoided. PMC

11. Hydration planning during heat/illness – Extra fluids during fever, exercise, or hot weather. Purpose: keep urine dilute to cut stone risk spikes. Mechanism: prevents concentration-driven crystal formation. FDA Access Data

12. Dietary oxalate moderation when stones present – If calcium oxalate stones occur, moderate very high-oxalate foods while maintaining balanced calcium intake per clinician advice. Purpose: reduce oxalate load that can combine with calcium. Mechanism: less oxalate → less calcium oxalate supersaturation. FDA Access Data

13. Citrate-rich foods (e.g., citrus) as tolerated – Dietary citrate can complement medical citrate. Purpose: raise urinary citrate (a calcium-binding inhibitor) to lower stone risk. Mechanism: citrate complexes calcium and inhibits crystal growth; this mirrors the pharmacology of potassium citrate. FDA Access Data

14. Growth and pubertal monitoring – Regular height/weight and development checks in children. Purpose: ensure treatment normalizes growth trajectory. Mechanism: growth response is a real-world marker of bone healing with phosphate. PMC

15. Genetic counseling – Family education on inheritance and testing. Purpose: identify affected relatives early. Mechanism: HHRH is usually autosomal recessive due to SLC34A3 variants. PubMed

16. Pain-coping strategies & activity pacing – Heat, rest intervals, and low-impact cross-training. Purpose: manage bone/muscle pain while staying active. Mechanism: pacing reduces stress on undermineralized bone. PMC

17. Medication review to avoid stone-promoting agents – Check for drugs that raise urinary calcium or acid-base disturbances. Purpose: minimize additive risk. Mechanism: some agents alter renal handling; pharmacist review is protective. NCBI

18. Dental care – Regular dental checks if enamel defects or dentin issues arise in rickets. Purpose: prevent caries and tooth pain. Mechanism: early repair reduces structural complications in hypomineralized teeth. PMC

19. Bone-safe sports – Swimming/cycling instead of high-impact contact sports during active rickets. Purpose: lower fracture risk. Mechanism: reduces high-impact loads while strength builds. PMC

20. Structured follow-up plan – Scheduled labs (phosphate, calcium, PTH, 25-OH-D, 1,25-OH₂-D as indicated), urine calcium, and imaging timeline. Purpose: keep therapy on target and protect kidneys. Mechanism: lab-guided titration of phosphate and other measures. PMC

---

Drug treatments

1. Potassium phosphate (oral phosphate salts) – Core therapy (various oral phosphate products exist; some are marketed with non-FDA-approved labeling; hospitals may use FDA-approved IV potassium phosphate when oral therapy is not possible). Class: phosphate supplement. Dose/Time: oral doses are individualized; clinicians often divide total daily elemental phosphorus into 3–5 doses; IV is used only when enteral replacement is impossible (per label). Purpose/Mechanism: replaces phosphorus to correct hypophosphatemia and heal rickets; raising phosphate also lowers the drive for excess 1,25-OH₂-D and urinary calcium. Side effects: GI upset, diarrhea; IV risks include hyperkalemia/hyperphosphatemia and hypocalcemia if misdosed. Label evidence (IV form): Potassium Phosphates Injection is FDA-approved as a phosphorus source when oral/enteral is not possible. Off-label: chronic oral phosphate in HHRH. FDA Access Data+2FDA Access Data+2

2. Hydrochlorothiazide (HCTZ) – Off-label in HHRH to reduce urinary calcium if hypercalciuria/stone risk persists despite phosphate therapy. Class: thiazide diuretic. Typical dose: 12.5–25 mg once daily (per label for hypertension; dosing and monitoring are individualized). Purpose/Mechanism: increases renal calcium reabsorption in the distal tubule → lowers urinary calcium and stone risk. Side effects: low potassium/sodium, photosensitivity, gout, glucose changes; monitor labs. Label reference; mechanistic evidence for calciuria lowering. FDA Access Data+1

3. Chlorthalidone – Off-label in HHRH. Class: thiazide-type diuretic. Typical dose: 12.5–25 mg once daily (label antihypertensive doses). Purpose/Mechanism: longer-acting thiazide-type agent; reduces urinary calcium similar to HCTZ; may help recurrent stones in selected patients. Side effects: similar to HCTZ; monitor electrolytes and uric acid. Label and calciuria data in general stone literature. FDA Access Data+2PMC+2

4. Indapamide – Off-label in HHRH. Class: thiazide-like diuretic. Typical dose: 1.25–2.5 mg daily (label antihypertensive dosing). Purpose/Mechanism: reduces urinary calcium; sometimes chosen for longer half-life. Side effects: similar to thiazides. Label reference and general stone evidence. FDA Access Data+2FDA Access Data+2

5. Potassium citrate (Urocit-K®) – Off-label in HHRH; on-label for hypocitraturic calcium stones. Class: urinary alkalinizer/citrate supplement. Typical dose: individualized to restore urinary citrate; label instructs combining with low salt and high fluid and titrating to urine citrate targets. Purpose/Mechanism: citrate binds calcium and inhibits calcium crystal growth; useful if hypocitraturia or stone risk persists. Side effects: GI upset, hyperkalemia risk in CKD or with certain drugs. Label evidence. FDA Access Data

6. Acetaminophen (paracetamol) – Symptom adjunct. Class: analgesic/antipyretic. Typical dose: per label max daily dose (e.g., up to 3,000–4,000 mg/day in adults depending on product and guidance). Purpose/Mechanism: relieves bone/muscle pain without affecting calciuria. Side effects: liver toxicity at high doses or with alcohol; follow label exactly. (Use U.S. OTC label; consult local brand label.) FDA Access Data

7. Ibuprofen/NSAIDs – Symptom adjunct, short-term. Class: NSAID. Typical dose: per OTC label depending on product strength; avoid if kidney function is impaired or with certain comorbidities. Purpose/Mechanism: anti-inflammatory analgesia for bone pain. Side effects: GI upset/bleeding risk, kidney effects—use cautiously in kidney disease; many clinicians prefer acetaminophen first. (Use FDA OTC labeling for specific product.) FDA Access Data

8. Tamsulosin – Off-label for stone passage facilitation in appropriate adults. Class: α-1 blocker. Typical dose: 0.4 mg once daily (BPH label). Purpose/Mechanism: relaxes ureteral smooth muscle to help pass distal ureteral stones. Side effects: dizziness, orthostatic hypotension; avoid in pregnancy; pediatric use is specialist-guided. Label evidence for drug; stone passage is off-label. FDA Access Data+1

9. Magnesium repletion (e.g., magnesium oxide) – Adjunct when deficient. Class: mineral supplement. Dose: individualized. Purpose/Mechanism: magnesium can complex oxalate and support bone-muscle function; corrects deficiency states that may worsen cramps or stones. Side effects: diarrhea; caution in CKD. (General supplement; check specific product labeling.) PMC

10. IV potassium phosphate (hospital use only) – When severe hypophosphatemia and oral therapy is not possible. Class: phosphate replacement. Dose: per FDA label using mmol phosphorus and mEq potassium calculations; requires cardiac/biochemical monitoring. Purpose/Mechanism: rapidly restores phosphorus. Side effects: hypocalcemia, hyperkalemia, infusion reactions; avoid mixing with calcium-containing solutions. Label evidence. FDA Access Data+1

11. Hydration therapy (oral rehydration solutions) – Supportive product use. Class: oral rehydration salts. Dose: per label during illness/heat. Purpose/Mechanism: protects against concentrated urine that promotes stones. Side effects: rare when used as directed. (Use specific product’s FDA OTC label.) FDA Access Data

12. Pain flares: topical analgesics (menthol/capsaicin) – Symptom adjunct. Class: topical analgesic. Dose: per OTC label. Purpose/Mechanism: local pain relief to reduce systemic NSAID use. Side effects: skin irritation. (Use specific product label.) FDA Access Data

Why not active vitamin D (calcitriol) as a “drug treatment”? In HHRH, routine calcitriol worsens hypercalciuria and nephrocalcinosis; the recommended approach is phosphate without active vitamin D unless a specialist identifies a special indication. PMC+1

Transparency note: There are not 20 distinct, evidence-based, FDA-labeled drug options specifically for HHRH. Beyond phosphate replacement and stone-risk management, additional agents are supportive or off-label and should be used only under specialist care. I avoided inventing or mislabeling drugs as “HHRH treatments.”

---

Dietary molecular supplements

1. Citrate (dietary and prescribed potassium citrate): As food or medication, citrate binds calcium and inhibits calcium oxalate crystal growth, lowering stone risk; labels pair citrate with high fluids and low salt. Dose: medical citrate is titrated to urine citrate targets; food amounts vary. Function: stone risk reduction. Mechanism: calcium complexation and crystal inhibition. FDA Access Data

2. Phosphate from food sources: Lean meats, dairy (if appropriate), and legumes provide phosphate that complements prescribed phosphate therapy. Dose: dietitian-guided. Function: supports bone mineralization. Mechanism: increases available phosphate to the body. PMC

3. Magnesium (if low): Magnesium participates in bone/muscle function and complexes oxalate in urine. Dose: individualized. Function: reduces stone risk in select patients and corrects deficiency. Mechanism: magnesium-oxalate complexation and cellular cofactor roles. PMC

4. Citrate-rich beverages (e.g., lemon/lime drinks, unsweetened): Dietary adjunct to raise urinary citrate modestly. Dose: varies; avoid excess sugar. Function: stone prevention. Mechanism: increases urinary citrate and pH. FDA Access Data

5. Adequate calcium intake (not excess): Normal dietary calcium (age-appropriate) helps bind gut oxalate and support bone, while avoiding calcium supplements unless prescribed. Function: lowers oxalate absorption and supports bone. Mechanism: Ca-oxalate binding in gut. FDA Access Data

6. Balanced protein intake: Adequate but not excessive animal protein; high purine/protein loads can boost stone risk in susceptible people. Function: reduce stone drivers while meeting growth needs. Mechanism: affects urinary calcium, citrate, and uric acid. FDA Access Data

7. Low-sodium eating pattern: As above, lower sodium reduces urinary calcium. Function: stone prevention and supports thiazide effect if used. Mechanism: sodium-calcium renal coupling. FDA Access Data

8. Fiber-rich foods: Support GI health when taking phosphate supplements that may cause diarrhea or cramps. Mechanism: stool-bulking and microbiome support. PMC

9. Adequate hydration strategy (scheduled water): Spreads intake over the day to maintain dilute urine. Function: lower supersaturation of calcium salts. Mechanism: urinary dilution. FDA Access Data

10. Avoid high-dose “bone” supplements without indication: Skip unneeded high-dose vitamin D or calcium pills unless your specialist prescribes them, to avoid worsening hypercalciuria. Mechanism: excessive calcium or active vitamin D can raise urinary calcium. PMC

---

Immunity boosters / regenerative / stem-cell drugs

There are no FDA-approved immunity boosters, regenerative medicines, or stem-cell drugs for HHRH. Using such products for HHRH would be unproven and potentially unsafe. Management relies on phosphate replacement and stone-risk reduction, with careful monitoring by nephrology/endocrinology. PMC

---

Surgeries

1. Corrective osteotomy – Orthopedic surgery to realign a significantly bowed limb that does not remodel after adequate phosphate therapy and growth. Why: improve function, gait, and pain when deformity is severe/persistent. PMC

2. Ureteroscopy (URS) for obstructing stones – Endoscopic fragmentation/extraction of ureteral stones. Why: relieve obstruction and pain when spontaneous passage is unlikely or risky. FDA Access Data

3. Percutaneous nephrolithotomy (PCNL) – Minimally invasive removal of large kidney stones. Why: treat stone burden that cannot be cleared by shock wave lithotripsy or URS. FDA Access Data

4. Shock wave lithotripsy (SWL) – External shock waves break smaller stones. Why: non-invasive option for select stones. FDA Access Data

5. Guided bone biopsies/orthopedic fixation for fractures – For atypical or non-healing fractures in rickets. Why: stabilize bone to allow healing alongside metabolic therapy. PMC

---

Preventions

1. Take phosphate exactly as prescribed and attend all follow-ups. Why: stabilizes bone and reduces hypercalciuria drive. PMC

2. Maintain high fluid intake daily; more during heat/fever. Why: dilute urine and prevent stones. FDA Access Data

3. Limit sodium (processed foods, added salt). Why: reduce urinary calcium. FDA Access Data

4. Don’t self-start active vitamin D analogs. Why: can worsen hypercalciuria. PMC

5. Moderate very high-oxalate foods if you have calcium oxalate stones. Why: less stone substrate. FDA Access Data

6. Target normal dietary calcium (not excess). Why: binds oxalate in gut and supports bone. FDA Access Data

7. Consider citrus intake or medical citrate if hypocitraturia exists. Why: citrate is a stone inhibitor. FDA Access Data

8. Use thiazide-type diuretics only if your specialist advises. Why: benefits require monitoring and vary by patient. PMC+1

9. Monitor urine and kidneys with your care team’s schedule. Why: catch stones/nephrocalcinosis early. PMC

10. Educate family; consider genetic testing for at-risk relatives. Why: earlier diagnosis → better outcomes. PubMed

---

When to see a doctor

See your clinician promptly for new bone pain, limping, fractures, or slowed growth in a child; for flank pain, visible blood in urine, fevers with urinary symptoms, or reduced urine output; or for vomiting/diarrhea that prevents you from keeping up with phosphate or fluids. Urgent care is warranted for severe pain with suspected obstructing stones, high fever with chills, or signs of dehydration. These steps protect bones and kidneys while treatment is optimized. PMC

---

What to eat and what to avoid

1. Eat: balanced meals with adequate protein and natural phosphate sources (e.g., lean meats/legumes) as advised. Avoid: extreme low-phosphate fad diets. PMC

2. Eat: citrus or other citrate-containing foods. Avoid: excessive sugar-sweetened beverages that add calories without benefit. FDA Access Data

3. Eat: normal dietary calcium with meals. Avoid: high-dose calcium supplements unless prescribed. FDA Access Data

4. Drink: water throughout the day. Avoid: chronically low fluid intake. FDA Access Data

5. Season: herbs/spices. Avoid: heavy salting and very salty packaged foods. FDA Access Data

6. Choose: moderate animal protein portions. Avoid: very high-protein crash regimens. FDA Access Data

7. Consider: oxalate-moderation if you form calcium oxalate stones. Avoid: routinely mega-dosing spinach, nuts, rhubarb without balance. FDA Access Data

8. Balance: fiber for gut comfort on phosphate therapy. Avoid: trigger foods if you notice GI side effects. PMC

9. Follow: your personalized dietitian plan. Avoid: internet “stone diets” not tailored to your labs. PMC

10. Ask before supplements. Avoid: starting vitamin D analogs or high-dose minerals without approval. PMC

---

Frequently Asked Questions

1) Is HHRH the same as X-linked hypophosphatemia?
No. HHRH is usually due to SLC34A3 mutations (NaPi-IIc) and is FGF23-independent, with high 1,25-OH₂-D and hypercalciuria; XLH is FGF23-mediated and typically requires active vitamin D plus phosphate (and, in some, anti-FGF23 therapy). PubMed

2) Why does HHRH cause kidney stones?
High 1,25-OH₂-D increases calcium absorption → high urine calcium; combined with phosphate handling, crystals can form. Hydration, salt reduction, and (if needed) thiazide/citrate aim to lower risk. PMC+1

3) Will phosphate alone fix my bones?
Many patients improve on oral phosphate alone; your clinician adjusts dose and monitors growth, radiographs, and labs. Active vitamin D is usually avoided. PMC+1

4) How is HHRH diagnosed?
By low serum phosphate with renal phosphate wasting, high/normal 1,25-OH₂-D, hypercalciuria, and confirmatory genetic testing of SLC34A3. PubMed

5) Do carriers get symptoms?
Carriers can occasionally have milder features, and related genes (SLC34A1 vs SLC34A3) associate with overlapping phenotypes; specialists interpret results in context. ScienceDirect

6) Are thiazides safe for kids?
They can be used by specialists with careful dose and lab monitoring; benefits and risks are individualized. FDA Access Data

7) What urine goals matter?
High volume, lower sodium, adequate citrate, and lower urinary calcium help reduce stone risk; your team may use 24-hour urine tests. FDA Access Data

8) Can I take vitamin D?
Your clinician may correct deficiency carefully, but routine active vitamin D (calcitriol/alfacalcidol) is avoided in HHRH because it worsens hypercalciuria. PMC

9) What if I can’t take pills during illness?
Contact your clinician; severe hypophosphatemia may require supervised IV phosphate replacement in hospital. FDA Access Data

10) Will I need surgery on my legs?
Some children with severe deformity require corrective osteotomy if bones don’t remodel after metabolic control. PMC

11) How often should I be seen?
Regular labs and imaging are scheduled by your specialist to titrate phosphate and protect kidneys. PMC

12) Are there gene or stem-cell cures?
Not at present for HHRH. Treatment is supportive and targeted at phosphate loss and stone risk. PMC

13) Is HHRH lifelong?
It’s genetic, so the predisposition is lifelong; treatment needs may change with age, growth, and pregnancy planning. PMC

14) Can adults be diagnosed for the first time?
Yes—some adults present with recurrent stones or bone pain and are diagnosed later by genetic testing and labs. PubMed

15) What specialists should I see?
Pediatric or adult nephrology and endocrinology for metabolic management; urology for stones; orthopedics for deformity; dietetics and genetics as needed. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.

PDF Documents For This Disease Condition References